Insights

Insights

Perspective, tips, and resources for moving health forward

All Insights Health Systems Pharmacies Physician Practices Manufacturers Animal Health

AmerisourceBergen

Forging ahead with US and EU healthcare policy changes: balancing sustainability, innovation and patient access in the era of IRA and EU HTA

AmerisourceBergen

June 2024

Webinar on-demand - A Panel Discussion on Navigating Medical Devices in Canada

AmerisourceBergen

Shot of a young businesswoman using a digital tablet and laptop while working in her home office

Manufacturers

Recap AMCP 2024: Our thought leadership in action

AmerisourceBergen

amcp

Manufacturers

Webinar: Bracing for the Impact of Biosimilars: Navigating Terrain in the U.S. Market Landscape

FormularyDecisions

Chemical chain

Q&A Interview: Navigating the launch of ATMPs in Europe

AmerisourceBergen

regulatory services_top banner

Manufacturers

Benefit-driven pricing: How AMNOG strikes a balance between the financial burden on statutory health insurance and reimbursement of innovative medications in Germany

Annika Brosig, PhD; Kristina Dittrich, PhD; Werner Kulp, PhD; Jan-Frederik Löpmeier-Röh, MSc; Edith Wehage, PhD

AMNOG strikes a balance

Manufacturers

Embarking on the EU HTAR realization journey: Key insights from the first of six implementing acts

Mareike Konstanski, MSc; Susanne Kossow, PhD; Ruairi O'Donnell, PhD; Kim Joline Schmidt, MSc

HTA JCA implementing acts

Manufacturers

EAMS evidence: A key player in drug value proposition and NICE approval?

David Ringger; Erika Wissinger, PhD

EAMS

Manufacturers

HTAQ Summer 2024

AmerisourceBergen

In this edition, we continue the series on preparations for European Union (EU) HTA now the draft implementing act on procedural rules for Joint Clinical Assessment (JCA) of medicinal products has been published. Additionally, two country-specific analyses consider the impact of AMNOG benefit assessment on drug pricing in Germany, and the impact of participation in the UK’s Early Access to Medicines Scheme (EAMS) on recommendations from the National Institute for Health and Care Excellence (NICE).

Manufacturers

Government Reliance on Value Assessments in Medicare Part B

AmerisourceBergen

abstract lines

Manufacturers

Rating the robots: Artificial intelligence for literature reviews

Malia Gill, MS; Kimberly Ruiz, EdM; Fi Stewart, MSc; Erika Wissinger, PhD

Rating AI for Lit reviews

Manufacturers

It’s Just…So…Cool – Don’t miss your opportunity for JSC!

Kim Joline Schmidt, MSc; Mareike Konstanski, MSc; Erika Wissinger, PhD; Patrick Blank, PhD

Awaiting the JCA implementing acts

Manufacturers

Apples to apples, or apples to oranges? Comparing the Inflation Reduction Act to drug-pricing programs in other countries

Scott Shields, MBA

Advanced therapies week

Manufacturers

Anticipating the top seven global market access trends for 2024: Cencora’s healthcare landscape outlook

AmerisourceBergen

global market access trends in 2024

Manufacturers

Patients at the center – Does the JCA truly embrace the patients’ voice?

AmerisourceBergen

EU JCA Patients at the center

Manufacturers

Unlocking the Potential of Joint Clinical Assessment (JCA) in Europe: Insights from Industry Leaders and Experts

AmerisourceBergen

bright tubes

Manufacturers

Webinar on demand: Implications of the EU JCA on patient access and engagement

AmerisourceBergen

PageDesign_Patient_Doc

Manufacturers

Does the EU HTAR really put patients at the center?

AmerisourceBergen

Does EU HTAR put patients at the center

Manufacturers

The more things change, the more they stay the same? Reviewing ICER's revised value assessment framework

Kimberly Westrich, MA; Lisabeth Buelt, MPH

ICERs update VAF

Manufacturers

Navigating the way to the new EU JCA—Are biopharma companies, HTA bodies, patients, and clinicians sufficiently prepared?

Kim Joline Schmidt, MSc; Mareike Konstanski, MSc; Ruairi O'Donnell, PhD; Erika Wissinger, PhD; Herbert Altmann, PhD

EU JCA countdown

Manufacturers

How NICE there’s an app for that!

Jo Watts-James, MBA

NICE DHT's

Manufacturers

Gauge the impact: What does the striking down of a federal copay accumulator regulation mean for patients and copay programs?

AmerisourceBergen

US capitol color

Manufacturers

First 10 drugs for Medicare price negotiation announced under IRA

Corey Ford, MHA

Washington DC Capital

Manufacturers

Podcast: Collaborative perseverance to bring change to medicine access

AmerisourceBergen

insights into the workings of the JCA process

Pharmacies

3 ways your distributor can help you prepare for DSCSA compliance

AmerisourceBergen

People

Manufacturers

Recap AMCP 2023: Our thought leadership in action

Team members at the AMCP 2023 exhibit

Manufacturers

Optimize your pre-approval information exchange strategy

Charles Dragovich

Abstract photography showing blue and white lines with a sense of motion

Evolving advanced therapy medicinal product regulations require new logistics complexity

Regualatory article 2

Regulators tightening cell and gene therapies logistics controls to assure patient safety and security

Regulatory article 3

Manufacturers

HTA Quarterly | Spring 2023

Time to adapt Europe’s evolving cell and gene therapy regulatory framework before it prevents patient access due to logistics hurdles

Image of European Medicines Agency head office sign

Pharmacies

DSCSA: Are you ready for November 2024?

AmerisourceBergen

Dist_Drug_A-Frame_Bottles_016

Manufacturers

Education: The centerpiece of biosimilar adoption

AmerisourceBergen

Biosimilars adoption

With landmark approval, spotlight on cryogenic logistics intensifies

blue genes

Manufacturers

HTA Quarterly | Summer 2023

Manufacturers

HTA Quarterly | Winter 2022

Manufacturers

Podcast: Conversations around interchangeability and biosimilar entries in new therapeutic categories

AmerisourceBergen

Interchangeable biosimilars

Manufacturers

Closing the gaps in pre-approval information exchange to accelerate product success and patient access

AmerisourceBergen

AB color abstract

Manufacturers

Market access abroad: Three reasons why early planning is critical for HTA countries

AmerisourceBergen

Abstract image of Red Color Illuminated Fiber Optics Selective Focus on Blue Background.

Manufacturers

Podcast: Milestones for biosimilars in 2022 and looking ahead to 2023

AmerisourceBergen

Biosimilars podcast

Patients lose if we don't continue to expand pharmacy-based clinical care in the U.S.

Kevin Ban; Jenni Zilka

Webinar: Debunking common PIE misperceptions to enhance your PIE strategy and tactics

Debunking PIE misperceptions

Physician Practices

Q&A: Legislative updates and healthcare advocacy report

doctor at computer

Manufacturers

Health policy and the political landscape

AmerisourceBergen

AB-health-policy

Affordability is about more than drug prices

abstract lines

Manufacturers

The Value of Real-World Evidence in Canadian Drug Commercialization: Part 2

Innomar Strategies

Manufacturers

Strategies for addressing copay accumulators: What manufacturers need to know

Corey Ford, MHA; Dale Hanna

copay accumulator piggy bank

Let's Ditch 2020 and Plan for 2021: Election What-Ifs

Republican Democrat Healthcare

Health Systems

Biosimilars: Patents, policy, and reimbursement

Sean McGowan; Steve Miller; David Senior

AmerisourceBergen

microphone

Physician Practices

COVID-19 Resources

AmerisourceBergen

COVID 19 Virtual Round Table Carousel_IQSS

Manufacturers

Commercializing in Canada: Quality Assurance and GMP Services

Innomar Strategies

Manufacturers

Commercializing in Canada: Regulatory Publishing and Submissions

Innomar Strategies

Physician Practices

How COVID-19 is Altering Telehealth

Featured article

iStock-1166115050

Physician Practices

Cybersecurity and Working Virtually During the Pandemic

AmerisourceBergen

iStock-995485400Blur

Health Systems

Partnering With Your Distributor for USP 800 Compliance

Darin Thornburgh

AmerisourceBergen

Pharmacist looks at medication.

Manufacturers

Mind the (Evidence) Gap

Kim McLeod, MPH

MindtheGap

Manufacturers

InnomarLive 2019: Commercializing in Canada

Innomar Strategies